The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®

The Clinical Study for Evaluating The Safety And Efficacy Of Epodion® During Maintenance Period Until Evaluation Period On CKD (Chronic Kidney Disease) Patients: An Open Label, Randomized, Active Drug-Comparative, Parallel-Designed, Multi-Center Clinical Study

The study was conducted to evaluate whether the efficacy and safety profile of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.

Study Overview

• Status: Completed
• Conditions: Chronic Kidney Disease (CKD)
• Intervention / Treatment: Biological: Recombinant Human Erythropoietin Alpha

Detailed Description

This was an open-label, randomized, active drug-comparative, parallel-designed, multi-center study in hemodialysis patients with anemia.

This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection. The primary endpoints of efficacy evaluation were to demonstrate that treatment of test product was equivalence with the reference product by evaluating Hb level change between baseline (Week 5-8/9-12) and evaluation period (Week 33-36/37-40), while the secondary endpoints were to obtain data mean change in weekly dosage per kg body weight between the baseline period and the evaluation period, to calculate instability rate of Hb level during maintenance and evaluation period as defined when Hb level dropped below 8 g/dL or increased by more than 13 g/dL and to evaluate the Hb and hematocrit (Ht) level during maintenance and evaluation period. The safety evaluation was conducted based on the incidence of the adverse events of both local and systemic reactions.

• Study Type: Interventional
• Enrollment (Actual): 82
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Indonesia
  • Jakarta, Indonesia, 10410
    • Gatot Soebroto Army Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 74 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female patients who are at least 18 years old and younger than 75 years of age at the time of screening visit.
• Patients with End-Stage Renal Failure (ESRD) who are chronically receiving hemodialysis and have anemia.
• Patients with a mean baseline Hb concentration within Hb level ≥ 9 g/dL during the screening period.
• Haemodialysis patients with anemia associated with Chronic Kidney Disease (CKD) currently receiving stable maintenance therapy with Epoetin alfa at least once per week
• Adequate iron substitution status (serum ferritin ≥ 100 μg /dl or saturated transferrin levels ≥ 20%).
• Patients who understand the information provided to them or their representatives and may provide written consent.

Exclusion Criteria:

• Contraindication with Epoetin therapy.
• Documented active bleeding in the last 12 weeks prior to screening period.
• Any blood transfusion within the last 2 weeks prior Screening period.
• History of malignancy of any organ system within the last 5 years.
• Patients with uncontrolled hypertension (in case the mean value of diastolic blood pressure as measured 4 times during the baseline observation period is 110 mmHg or more).
• Patients hyporesponsive epoetin treatment or had medical history of experiencing pure red blood cell forming failure after being administered with Epoetin products.
• Known bone marrow fibrosis (osteitis fibrosa cystica).
• Patient with serious cardiovascular disorders: myocardial infarction, patients with congestive heart failure (NYHA class Ⅲ or higher), ischemic vascular disease
• Patient received percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) during the last 6 months prior to screening.
• Patient with the following liver disorder: Patient diagnosed with liver cirrhosis, hepatitis B, or on active treatment hepatitis C, and patients with ALT or AST exceeding the upper limits of the normal level by more than double.
• Patients whose kidney transplant is expected or already planned for survival.
• Secondary anemia to other causes different to the CKD (aplastic anemia, hemolytic anemia, sickle cell anemia, multiple myeloma, leukemia, myelodysplastic syndrome).
• Patients with the following diseases and who are considered unfit to enroll in the clinical study: mental system disease, mental disease, drug intoxication, epilepsy, lung infarction, cerebral infarction, positive HIV antibody, systemic lupus erythematosus, immunosuppressive condition and general infection
• Pregnancy or lactation period in female patients, or women of childbearing potential without an effective method of birth control.
• Patients who were considered unfit for study by the principal investigators or by the co-investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test Drug; Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL	Biological: Recombinant Human Erythropoietin Alpha; This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
Active Comparator: Reference Drug; Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL	Biological: Recombinant Human Erythropoietin Alpha; This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hb level change	Hb level change between Test and Reference Drug	baseline (Week 5-8/9-12) and evaluation period (Week 33-36/37-40).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
mean change in weekly dosage per kg body weight	Dosage for Mean change in mg/Kg Body Weight	baseline (Week 5-8/9-12) and evaluation period (Week 33-36/37-40).

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
instability rate of Hb (hemoglobin)	instability rate of Hb in Percent (%)	maintenance (week 10-14/32-36) and evaluation period (Week 33-36/37-40)
Hb (hemoglobin) and hematocrit level	Hb (hemoglobin) in gram/desiLiter and hematocrit level in Percent (%)	maintenance (week 10-14/32-36) and evaluation period (Week 33-36/37-40)
incidence of adverse event	incidence of adverse event between Test and Reference Drug	during the study evaluation from baseline (Week 5-8/9-12) to evaluation period (Week 33-36/37-40)

Collaborators and Investigators

• Sponsor: PT. Daewoong Infion
• Collaborators: Equilab International
• Investigators: Principal Investigator: Jonny Jonny, MD, Gatot Soebroto Army Hospital, Jakarta

Study record dates

Study Major Dates

• Study Start (Actual): November 7, 2019
• Primary Completion (Actual): May 15, 2021
• Study Completion (Actual): January 28, 2022

Study Registration Dates

• First Submitted: April 26, 2022
• First Submitted That Met QC Criteria: May 12, 2022
• First Posted (Actual): May 13, 2022

Study Record Updates

• Last Update Posted (Actual): July 14, 2022
• Last Update Submitted That Met QC Criteria: July 12, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic; Hematinics; Epoetin Alfa
• Other Study ID Numbers: DW_EPO401

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No